|
|
-
Pharmacodynamic concepts and
their definitions (Inga Odenholt, Sweden)
-
Which antibiotic concentrations
should be used to determine pharmacokinetic/pharmacodynamic relationships
for efficacy ? (Otto Cars, Sweden)
-
Standardization of pharmacokinetic
comparisons between drugs (Fritz Sörgel, Germany)
-
Can pharmacokinetic/pharmacodynamic
in vitro modelling help us to define optimal dosing regimens ?
(Johan Mouton, The Netherlands)
-
The use of in vitro models to
predict emergence of resistance (Jürg Bläser,
Switzerland)
-
The use of animal models to
define breakpoints for susceptibility (William Craig,
U.S.A.)
-
Can we define breakpoints for
intracellular infections? (Paul M. Tulkens, Belgium)
-
Population pharmacokinetics.
What is it? How should we use it? (Sander Vinks, The
Netherlands)
-
Pharmacokinetic/pharmacodynamic
interactions: Tools for improvment of clinical trials and design of clinical
trials (George Drusano, U.S.A.)
-
The role of antibiotic pharmacodynamics
in drug development: regulatory aspects (Bo Aronsson,
U.K.)
-
PANEL DISCUSSION: Pharmacodynamics
of antibiotics - consequences for dosing. (Niels Frimott-Möller,
convenor, Denmark)
|
Back
to ISAP home page